Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Nov 01, 2019

SELL
$12.44 - $17.48 $464,012 - $652,004
-37,300 Closed
0 $0
Q1 2019

Apr 24, 2019

BUY
$11.11 - $25.6 $414,403 - $954,880
37,300 New
37,300 $671,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $200M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.